Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
Follow AGEN
Agenus Inc. (AGEN) P/E ratio
As of 16 October 2026, Agenus Inc. (AGEN) trades at a P/E ratio of 2.3×. Over the past ten years it has ranged from 0.0× (March 2026) to 22.0× (August 2022); the current reading is higher than 95% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 1.2× | (42.53%) |
| Mar 2026 | 2.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SRZN Surrozen, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| AGEN Agenus Inc. | 2.3× |
| CYPH Cypherpunk Technologies Inc. compare | 4.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)